<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076529</url>
  </required_header>
  <id_info>
    <org_study_id>RamosetronPK</org_study_id>
    <nct_id>NCT02076529</nct_id>
  </id_info>
  <brief_title>Phamacokinetic and Pharmacodynamic Study of Ramosetron in Chemotherapy Induced Nasea and Vomiting</brief_title>
  <official_title>A Study About Pharmacokinetic and Pharmacodynamics of Ramosetron in Chemotherapy Induced Nausea and Vomiting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chonnam National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designted to know optimal dose of Ramosteron to control for chemotherapy
      induced nasea and vomoting (CINV)based on its pharmacokinetics, pharmacodynamic study and
      clinilcal parameters using Rhodes Index.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nausea and vomiting is a common adverse event during chemotherapy treatment. Even if
      preventive medicines such as dopamine receptor antagonist, corticosteroid, serotonin receptor
      antagonist, has been developed and used, there is residual nausea and/or vomiting in a
      significant percentage of patients treated for cancer. Serotonin receptor antagonist is the
      most potent antiemetic agent and has been used widely. However, the optimal dose of serotonin
      antagnosit based on individual symptoms is not defined. Therefore, this study was conducted
      to design standardization model for optiomal serotonin antagonist concentration using
      pharmacodynamic study and Rhodes Index as a suggogate marker for CINV.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of Ramosetron according to 3 level of dose</measure>
    <time_frame>10min to 48 hours post-dose</time_frame>
    <description>Pharmacokinectics using NONMEM will be analyzed from serum after Ramosetron injection from 10 min to 48 hours (10min, 1hr, 6hr, 24hr, 48hr)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rhodes Index</measure>
    <time_frame>1 hour to seven days post-dose</time_frame>
    <description>Monitor using Rhodes Index will be performed each time at 1hour, 6hour, 24hour, 48hour and seven dyas after Ramosetron injection</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Ramosetron 0.6mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramosetron 0.6mg intravenous injection 30min before chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramosetron 0.45mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ramosetron 0.45mg intravenous injection 30min before chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ramosetron 0.3mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ramosetron 0.3mg intravenous injection 30 min before chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron 0.3mg</intervention_name>
    <arm_group_label>Ramosetron 0.3mg</arm_group_label>
    <other_name>Nasea 0.3mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron 0.45mg</intervention_name>
    <arm_group_label>Ramosetron 0.45mg</arm_group_label>
    <other_name>Nasea 0.45mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron 0.6mg</intervention_name>
    <arm_group_label>Ramosetron 0.6mg</arm_group_label>
    <other_name>Nasea 0.6mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who recevied moderate emetogenic chemotherapy

          -  Age between 18-75

          -  ECOG PS 0-2

          -  Adequate organ fuction including bone marrow, liver and kidney

        Exclusion Criteria:

          -  Gastrointestinal obstruction or carcinomatosis peritonei

          -  CNS metastasis or disability in CNS

          -  Intractable medical illness

          -  Pregnancy or inadequate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sang-Hee Cho, M.D.Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CNUHH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chonnam National University Hwasun Hospital</name>
      <address>
        <city>Gwangju</city>
        <state>Jeollanamdo</state>
        <zip>519-809</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <last_update_submitted>February 28, 2014</last_update_submitted>
  <last_update_submitted_qc>February 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chonnam National University Hospital</investigator_affiliation>
    <investigator_full_name>Sang-Hee Cho</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>chemotherapy induced nausea vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

